PLYX.US Polaryx Therapeutics, Inc. Common Stock

Healthcare Biotechnology USA Stocks
1.60 USD
Close of Nov 18, 2026
1.56 48.91
Market cap
USD 75.7M
P/E
-
P/B
10.94x
ROE
-127.0%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is PLYX.US undervalued?

Graham number

The Graham number of Polaryx Therapeutics, Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Polaryx Therapeutics, Inc. Common Stock fundamental analysis

No fundamental analysis for Polaryx Therapeutics, Inc. Common Stock yet.

Polaryx Therapeutics, Inc. Common Stock stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Polaryx Therapeutics, Inc. Common Stock

Polaryx Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of disease-modifying therapies for rare and pediatric lysosomal storage disorders in the United States. Its pipeline includes PLX-100, a preclinical stage orally administrable combination therapy; PLX-200, a repurposed oral small molecule for the treatment of LSDs; PLX-300, a preclinical stage orally administrable combination therapy; and PLX-400, …

Full company profile